Abstract:
PURPOSE: A method for determining nephrotoxicity using concentration change of acetate and trimethylamine-N-oxide(TMAO) contained in urine is provided to ensure high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring the concentration 1 of acetate and trimethylamine-N-oxide(TMAO) contained in urine which is injected with a drug; a step of comparing the concentration 2 of acetate and TMAO contained in urine from a control group; and a step of determining whether the concentration 1 is significantly changed.
Abstract:
PURPOSE: A method for determining nephrotoxicity of a drug using concentration change of acetate and citrate contained in urine is provided to ensure high sensitivity and specificity and to develop a safety novel drug. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring the concentration 1 of acetate and citrate contained in urine from a drug-injected individual; a step of comparing the concentration 1 with the concentration 2 of acetate and citrate contained in urine from a control group; and a step of determining whether the concentration 1 is significantly changed. The individual is a mammal exclusive of humans.
Abstract:
PURPOSE: A method for discriminating nephrotoxicity of a drug and a method for screening a nephrotoxicity-inducing material are provided to accurately determine nephrotoxicity with high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring concentration 1 of acetate and dimethyl glycine contained in urine from a drug-injected individual; a step of comparing concentration 1 with concentration 2 of acetate and dimethyl glycine contained in urine from a control group; and a step of determining whether concentration 1 is significantly changed. A method for screening a nephrotoxicity-inducing material comprises: a step of injecting a test composition or a test compound into an individual as an experimental group; a step of measuring and comparing the concentration of acetate and dimethyl glycine contained in urine from a control group; and a step of selecting a test composition or test compound which significantly changes the concentration of acetate and dimethyl glycine compared with the control group.
Abstract:
PURPOSE: A transgenic Alzheimer's mice expressing APPsw gene and a preparation method thereof are provided to show almost perfect Alzheimer symptoms and to be used in developing an Alzheimer treatment and an early diagnosis manner. CONSTITUTION: The preparation method of the transgenic Alzheimer's mice expressing APPsw(Amyloid precursor protein swedish) gene comprises the steps of: preparing a recombinant fusion gene by connecting an APPsw gene to a promoter of a NSE(Neur on-Specific Enolase) gene; microinjecting the recombinant fusion gene into a fertilized egg of a mouse; and breeding by nidating the fertilized egg into an abduct of a surrogate mother mouse.
Abstract:
PURPOSE: A transgenic dementia mouse expressing a mutant PS2 gene and a manufacturing process thereof are provided to be utilized usefully in treating a dementia disease or improving an early diagnosis process of the disease. CONSTITUTION: The manufacturing process of the transgenic dementia mouse expressing a mutant PS2 gene comprises the steps of: preparing a hybrid gene NSE/hPS2m by connecting to a promoter of a neuron-specific enolase gene to a mutant PS2 dementia gene derived from a human; micro-injecting the hybrid gene into a fertilized egg of a mouse; and implanting the fertilized egg into an oviduct of a surrogate mother mouse.